STAHL, Circuit Judge.
In September 2015, Ocular Therapeutix, Inc. ("Ocular" or the "company"), a public, Massachusetts-based biopharmaceutical company, submitted a New Drug Application ("NDA") to the United States Food and Drug Administration ("FDA") for approval of its drug product, Dextenza,
Let's get started
Welcome to the leading source of independent legal reporting
Sign on now to see your case.
Or view more than 10 million decisions and orders.
- Updated daily.
- Uncompromising quality.
- Complete, Accurate, Current.